Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform

Tools

Genmab Enters Broad Collaboration with Janssen Biotech, Inc. for DuoBody Platform

Genmab enters DuoBody™ technology collaboration
$3.5 million upfront payment to Genmab

Copenhagen, Denmark; July 12, 2012 — Genmab A/S (OMX: GEN) announced today it has entered into a collaboration with Janssen Biotech, Inc. and its affiliates ("Janssen") to create and develop bispecific antibodies using its DuoBody technology platform.  Genmab will create panels of bispecific antibodies to multiple disease target combinations identified by Janssen, who will in turn fully fund research at Genmab.

Under the terms of the agreement, Genmab and Janssen will collaborate on the research of up to 10 DuoBody programs and Genmab will receive an upfront payment of $3.5 million (DKK 21 million) from Janssen and all research by Genmab will be fully funded by Janssen. In addition, Genmab will potentially be entitled to milestone and license payments of up to approximately $175 million (DKK 1,062 million) for each product as well as royalties on any commercialized products.

"Since the introduction of our DuoBody platform in 2010, we have believed in its potential to become the preferred technology for next generation bispecific antibody therapeutics.  Today's announcement is another indicator that the pharmaceutical industry recognizes our leadership in the therapeutic antibody field," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.  "We very much look forward to working with Janssen in creating trend-setting bispecific antibody treatments."

This agreement is not expected to have a material impact on Genmab's 2012 financial guidance.

About the DuoBody Platform
The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.

About Genmab A/S
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.  Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax®-EGFr; HuMax®-IL8; HuMax®-TAC; HuMax®-CD38; HuMax®-TF; HuMax®-TF-ADC; HuMax®-Her2; HuMax®-cMet, HuMax®-CD74, DuoBody™ and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Company Announcement no. 17
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K
Denmark